Evolent Health (EVH) Common Equity (2013 - 2026)

Evolent Health has reported Common Equity for 14 years, with the latest figure at $396.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 57.63% year-over-year to $396.4 million; the trailing twelve-month figure through Mar 2026 stood at $396.4 million (down 57.63% YoY), and the FY2025 full-year result was $415.2 million, down 58.53% from the prior year.
• Common Equity for Q1 2026 stood at $396.4 million, down from $415.2 million in the prior quarter.
• The five-year high for Common Equity was $1.1 billion in Q1 2023, with the low at $396.4 million in Q1 2026.
• Average Common Equity over 5 years is $879.2 million, with a median of $935.5 million recorded in 2025.
• Year-over-year, Common Equity soared 83.53% in 2023 and tumbled 58.53% in 2025.
• Tracing EVH's Common Equity over 5 years: stood at $859.4 million in 2022, then rose by 24.24% to $1.1 billion in 2023, then retreated by 6.22% to $1.0 billion in 2024, then plunged by 58.53% to $415.2 million in 2025, then declined by 4.53% to $396.4 million in 2026.
• The last three Common Equity figures came in at $396.4 million (Q1 2026), $415.2 million (Q4 2025), and $842.2 million (Q3 2025), per Business Quant data.

Peer Comparison